Teruhiko Higuchi

Meiji University of Integrative Medicine — Japan

Neuroscience · Life Sciences

40h-index5.4kcitations185works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tryptophan and brain disorders(37), Schizophrenia research and treatment(28), Bipolar Disorder and Treatment(27), Treatment of Major Depression(25), Stress Responses and Cortisol(23)

Publications185 total

In Memoriam: Dr. Shoji Naruse (1945–2025)
Magnetic Resonance Imaging·2026
PLASMA PHOSPHOETHANOLAMINE LEVELS AS A BIOMARKER FOR MONITORING MAJOR DEPRESSIVE DISORDER
The International Journal of Neuropsychopharmacology·2025Open Access
A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder
CNS Drugs·2024· 2 citedOpen Access
Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind (<scp>BLESS</scp>) study
Psychiatry and Clinical Neurosciences·2023· 8 citedOpen Access
Plasma Phosphoethanolamine Levels as a Biomarker for Monitoring Major Depressive Disorder
Research Square (Research Square)·2023Open Access
Author Correction: Improving polygenic prediction in ancestrally diverse populations
Nature Genetics·2022· 9 citedOpen Access
Improving polygenic prediction in ancestrally diverse populations
Nature Genetics·2022· 630 citedOpen Access
Corrigendum to “Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study”. [Journal of Affective Disorders 281 (2021) 160–167]
Journal of Affective Disorders·2021
Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
International Journal of Bipolar Disorders·2021· 8 citedOpen Access
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
Neuropsychiatric Disease and Treatment·2021· 12 citedOpen Access
Corrigendum to “Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study”. [Journal of Affective Disorders 281 (2021) 160–167]
Journal of Affective Disorders·2021
Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
Psychiatry and Clinical Neurosciences·2021· 25 citedOpen Access
Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study
Journal of Affective Disorders·2020· 8 citedOpen Access
<scp>Double‐blind</scp>, <scp>placebo‐controlled</scp> study of lurasidone monotherapy for the treatment of bipolar I depression
Psychiatry and Clinical Neurosciences·2020· 42 citedOpen Access
SAT0119 PARADOXICAL NEUTROPHIL ACTIVATION BY ANTI-IL6 THERAPY: TRANSCRIPTOME ANALYSIS SHOWS A RATIONALE FOR DERMATOLOGICAL ADVERSE REACTIONS AND DECREASED NEUTROPHIL COUNTS AFTER TOCILIZUMAB TREATMENT
Annals of the Rheumatic Diseases·2020
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
CNS Drugs·2019· 23 citedOpen Access
Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26‐week open‐label extension study
Asia-Pacific Psychiatry·2019· 10 cited
Promotion of Research and Development for Persons with Mental Illness
Asian College of Neuropsychopharmacology·2019
Safety and Tolerability of Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled 6-week Study (ELEVATE study)
Asian College of Neuropsychopharmacology·2019
Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
Schizophrenia Research·2019· 42 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Hiroshi Kunugi(20), Hiroaki Hori(16), Toshiya Teraishi(15), Kotaro Hattori(14), Miho Ota(12), Daimei Sasayama(11), Kunitoshi Kamijima(8), Sumiko Yoshida(8), Takamasa Noda(8), Junko Matsuo(6), Shigenobu Kanba(5), Mitsuhiko Yamada(5), Nakao Iwata(4), Takeo Yoshikawa(4), Norie Koga(4), Nagahisa Okamoto(4), Kota Sakamoto(4), Norio Ozaki(4), Anna Nagashima(4), Jun Ishigooka(4)